We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current OCUL market cap is 1.55B. The company's latest EPS is USD -0.5178 and P/E is -19.16.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 15.19M | 15.08M | 14.8M | 14.77M | 16.44M |
Operating Income | -20.57M | -19.21M | -20.05M | -31.62M | -43.59M |
Net Income | -20.68M | -516k | -29.22M | -64.85M | -43.78M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 4.23M | 17.4M | 43.52M | 51.49M | 58.44M |
Operating Income | -85.8M | -62.85M | -78.04M | -78.65M | -82.38M |
Net Income | -86.37M | -155.64M | -6.55M | -71.04M | -80.74M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 122.56M | 162.38M | 252.06M | 538.95M | 517.09M |
Total Liabilities | 119.47M | 154.53M | 160.93M | 130.96M | 139.4M |
Total Equity | 3.09M | 7.85M | 91.13M | 407.98M | 377.7M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 78.74M | 261.86M | 204.89M | 149.29M | 252.06M |
Total Liabilities | 82.37M | 185.77M | 116.89M | 113.91M | 160.93M |
Total Equity | -3.63M | 76.1M | 88M | 35.38M | 91.13M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -40.05M | -47.78M | -70.23M | -33.89M | -58.69M |
Investing | -5.37M | -5.63M | -6.09M | -255k | -997k |
Financing | 9.72M | 61.66M | 169.83M | 321.22M | 323.42M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -77.58M | -53.55M | -64.55M | -59.6M | -70.23M |
Investing | -2.24M | -841k | -1.19M | -3.72M | -6.09M |
Financing | 75.34M | 228.01M | 2.85M | 1.45M | 169.83M |
Market Cap | 1.55B |
Price to Earnings Ratio | -19.16 |
Price to Sales Ratio | 26.47 |
Price to Cash Ratio | 7.9 |
Price to Book Ratio | 16.97 |
Dividend Yield | - |
Shares Outstanding | 155.92M |
Average Volume (1 week) | 914.88k |
Average Volume (1 Month) | 858.43k |
52 Week Change | 352.97% |
52 Week High | 11.775 |
52 Week Low | 2.05 |
Spread (Intraday) | 8.14 (65.12%) |
Company Name | Ocular Therapeutix Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.ocutx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions